Answers are grounded in this paper and cite their sources.
Dr Ratain's commentaries on the drug sotorasib (the first approved KRAS inhibitor for NSCLC), which he describes as the poster child for Project Optimus, have helped to frame the argument for dose optimization as well as the challenges for clinical implementation. 4,5arbara Burtness, MD, a medical oncologist and co-leader of the Developmental Therapeutics Program at Yale Cancer Center, whose seminal work concerns de-intensifying the treatment of human papillomavirus-associated head and neck cancers and minimizing the late effects of curative therapy, sees dose optimization of molecular therapies as highly important."I think Project Optimus is a very laudable goal," she says.Others have been more cautious, however, and have expressed concern over potential drug delays 6 or the potential for ineffective doses to be selected if dose optimization is required in early phases of clinical trials. 7,8ddressing the concern over potential delays in drug approvals, Dr Burtness thinks that delays will be minimized as investigators and manufacturers develop agents in accordance with the FDA requirements as the project rolls out.Dr Ratain is not worried."I think approving a drug prematurely at an excessive dose is generally far worse than delaying approval," he says.
No takes yet. Share an insight, caveat, or question.
Mary Beth Nierengarten (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: